- Title: Subtitle
- Durability of Response in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1
- Creators
- Frederick L. Locke - Moffitt Cancer CenterArmin Ghobadi - Washington University in St. LouisCaron A. Jacobson - Dana-Farber Cancer InstituteEric Jacobsen - Dana-Farber Cancer InstituteDavid B. Miklos - Stanford UniversityLazaros J. Lekakis - University of Miami Health SystemIra Braunschweig - Albert Einstein College of MedicineOlalekan O. Oluwole - Vanderbilt UniversityYi Lin - Mayo Clinic, Rochester, Minnesota, United StatesTanya Siddiqi - City Of Hope National Medical CenterAbhinav Deol - Wayne State UniversityPatrick M. Reagan - University of RochesterUmar Farooq - University of IowaAdrian Bot - Kite (United States)Yizhou JiangJohn M. RossiAllen Xue - Kite (United States)William Y. Go - Kite (United States)Sattva S. Neelapu - The University of Texas MD Anderson Cancer Center
- Resource Type
- Abstract
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.18, pp.S277-S278
- DOI
- 10.1016/j.clml.2018.07.206
- ISSN
- 2152-2650
- eISSN
- 2152-2669
- Language
- English
- Date published
- 09/2018
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984362734702771
Abstract
Durability of Response in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1
Clinical lymphoma, myeloma and leukemia, Vol.18, pp.S277-S278
09/2018
DOI: 10.1016/j.clml.2018.07.206
Details
Metrics
9 Record Views